{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T22:39:38Z","timestamp":1770417578989,"version":"3.49.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,16]],"date-time":"2021-10-16T00:00:00Z","timestamp":1634342400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013220","name":"Ultragenyx Pharmaceutical","doi-asserted-by":"publisher","award":["UX007-CU302"],"award-info":[{"award-number":["UX007-CU302"]}],"id":[{"id":"10.13039\/100013220","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism Reports"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.ymgmr.2021.100814","type":"journal-article","created":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T04:04:46Z","timestamp":1634702686000},"page":"100814","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Triheptanoin \u2013 Novel therapeutic approach for the ultra-rare disease mitochondrial malate dehydrogenase deficiency"],"prefix":"10.1016","volume":"29","author":[{"given":"Alexander","family":"Laemmle","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea Lisa","family":"Steck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9","family":"Schaller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Kurth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eveline","family":"Perret Hoign\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea Deborah","family":"Felser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nedelina","family":"Slavova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Salvisberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana","family":"Atencio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fanny","family":"Mochel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Marc","family":"Nuoffer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Gautschi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ymgmr.2021.100814_bb0005","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ajhg.2016.11.014","article-title":"Mutations in MDH2, encoding a Krebs cycle enzyme, cause early-onset severe encephalopathy","volume":"100","author":"Ait-El-Mkadem","year":"2017","journal-title":"Am. J. Hum. Genet."},{"issue":"3","key":"10.1016\/j.ymgmr.2021.100814_bb0010","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.ajhg.2019.07.015","article-title":"Bi-allelic GOT2 mutations cause a treatable malate-aspartate shuttle-related encephalopathy","volume":"105","author":"van Karnebeek","year":"2019","journal-title":"Am. J. Hum. Genet."},{"issue":"2","key":"10.1016\/j.ymgmr.2021.100814_bb0015","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.jtbi.2008.05.033","article-title":"Role of the malate-aspartate shuttle on the metabolic response to myocardial ischemia","volume":"254","author":"Lu","year":"2008","journal-title":"J. Theor. Biol."},{"issue":"11","key":"10.1016\/j.ymgmr.2021.100814_bb0020","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1002\/iub.2367","article-title":"The malate-aspartate shuttle (Borst cycle): how it started and developed into a major metabolic pathway","volume":"72","author":"Borst","year":"2020","journal-title":"IUBMB Life"},{"issue":"4","key":"10.1016\/j.ymgmr.2021.100814_bb0025","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/jimd.12402","article-title":"Inborn disorders of the malate aspartate shuttle","volume":"44","author":"Broeks","year":"2021","journal-title":"J. Inherit. Metab. Dis."},{"issue":"3","key":"10.1016\/j.ymgmr.2021.100814_bb0030","first-page":"257","article-title":"Malate dehydrogenases\u2013structure and function","volume":"21","author":"Minarik","year":"2002","journal-title":"Gen. Physiol. Biophys."},{"issue":"2\u20133","key":"10.1016\/j.ymgmr.2021.100814_bb0035","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1007\/s10545-006-0290-3","article-title":"Anaplerotic diet therapy in inherited metabolic disease: therapeutic potential","volume":"29","author":"Roe","year":"2006","journal-title":"J. Inherit. Metab. Dis."},{"issue":"3","key":"10.1016\/j.ymgmr.2021.100814_bb0040","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/jimd.12199","article-title":"Therapeutic potential of triheptanoin in metabolic and neurodegenerative diseases","volume":"43","author":"Wehbe","year":"2020","journal-title":"J. Inherit. Metab. Dis."},{"issue":"11","key":"10.1016\/j.ymgmr.2021.100814_bb0045","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1002\/jnr.24111","article-title":"Triheptanoin for the treatment of brain energy deficit: a 14-year experience","volume":"95","author":"Mochel","year":"2017","journal-title":"J. Neurosci. Res."},{"issue":"6","key":"10.1016\/j.ymgmr.2021.100814_bb0050","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.ejpn.2018.07.014","article-title":"A pilot study of add-on oral triheptanoin treatment for children with medically refractory epilepsy","volume":"22","author":"Calvert","year":"2018","journal-title":"Eur. J.Paediatr. Neurol."},{"issue":"4","key":"10.1016\/j.ymgmr.2021.100814_bb0055","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/jnc.14275","article-title":"Triheptanoin protects against status epilepticus-induced hippocampal mitochondrial dysfunctions, oxidative stress and neuronal degeneration","volume":"144","author":"Tan","year":"2018","journal-title":"J. Neurochem."},{"issue":"15","key":"10.1016\/j.ymgmr.2021.100814_bb0060","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1007\/s40265-020-01399-5","article-title":"Triheptanoin: first approval","volume":"80","author":"Shirley","year":"2020","journal-title":"Drugs"},{"issue":"1\u20132","key":"10.1016\/j.ymgmr.2021.100814_bb0065","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ymgme.2015.06.006","article-title":"Long-term major clinical outcomes in patients with long chain fatty acid oxidation disorders before and after transition to triheptanoin treatment\u2013A retrospective chart review","volume":"116","author":"Vockley","year":"2015","journal-title":"Mol. Genet. Metab."},{"issue":"3","key":"10.1016\/j.ymgmr.2021.100814_bb0070","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1136\/jmedgenet-2013-101932","article-title":"Mutations in SDHD lead to autosomal recessive encephalomyopathy and isolated mitochondrial complex II deficiency","volume":"51","author":"Jackson","year":"2014","journal-title":"J. Med. Genet."},{"issue":"3","key":"10.1016\/j.ymgmr.2021.100814_bb0075","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1007\/s11306-019-1497-2","article-title":"Selective galactose culture condition reveals distinct metabolic signatures in pyruvate dehydrogenase and complex I deficient human skin fibroblasts","volume":"15","author":"Hertig","year":"2019","journal-title":"Metabolomics"},{"issue":"5","key":"10.1016\/j.ymgmr.2021.100814_bb0080","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet.Med."},{"issue":"2","key":"10.1016\/j.ymgmr.2021.100814_bb0085","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0925-4439(97)00035-5","article-title":"Inborn errors of the Krebs cycle: a group of unusual mitochondrial diseases in human","volume":"1361","author":"Rustin","year":"1997","journal-title":"Biochim. Biophys. Acta"},{"issue":"4","key":"10.1016\/j.ymgmr.2021.100814_bb0090","doi-asserted-by":"crossref","DOI":"10.3390\/children4040030","article-title":"Overview of four functional classification systems commonly used in cerebral palsy","volume":"4","author":"Paulson","year":"2017","journal-title":"Children"},{"issue":"3","key":"10.1016\/j.ymgmr.2021.100814_bb0095","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.nbd.2010.07.017","article-title":"Anticonvulsant effects of a triheptanoin diet in two mouse chronic seizure models","volume":"40","author":"Willis","year":"2010","journal-title":"Neurobiol. Dis."},{"issue":"14","key":"10.1016\/j.ymgmr.2021.100814_bb0100","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1007\/s00018-013-1539-2","article-title":"Regulation of pyruvate metabolism and human disease","volume":"71","author":"Gray","year":"2014","journal-title":"Cell.Mol. Life Sci."},{"key":"10.1016\/j.ymgmr.2021.100814_bb0105","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.mito.2017.12.002","article-title":"Succinate dehydrogenase: prospect for neurodegenerative diseases","volume":"42","author":"Jodeiri Farshbaf","year":"2018","journal-title":"Mitochondrion"},{"issue":"2","key":"10.1016\/j.ymgmr.2021.100814_bb0110","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/jcbfm.2012.151","article-title":"Heptanoate as a neural fuel: energetic and neurotransmitter precursors in normal and glucose transporter I-deficient (G1D) brain","volume":"33","author":"Marin-Valencia","year":"2013","journal-title":"J. Cerebral Blood Flow Metabol."},{"key":"10.1016\/j.ymgmr.2021.100814_bb0115","doi-asserted-by":"crossref","DOI":"10.1177\/2042018820938240","article-title":"Therapeutic potential of pyruvate therapy for patients with mitochondrial diseases: a systematic review","volume":"11","author":"Li","year":"2020","journal-title":"Therap.Adv.Endocrinol.Metabol."},{"issue":"44","key":"10.1016\/j.ymgmr.2021.100814_bb0120","doi-asserted-by":"crossref","first-page":"27414","DOI":"10.1016\/S0021-9258(18)47001-9","article-title":"Tricarboxylic acid cycle in rat brain synaptosomes. Fluxes and interactions with aspartate aminotransferase and malate\/aspartate shuttle","volume":"269","author":"Yudkoff","year":"1994","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.ymgmr.2021.100814_bb0125","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.pharmthera.2014.06.001","article-title":"Epilepsy, energy deficiency and new therapeutic approaches including diet","volume":"144","author":"Reid","year":"2014","journal-title":"Pharmacol. Ther."}],"container-title":["Molecular Genetics and Metabolism Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214426921001099?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214426921001099?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T12:53:27Z","timestamp":1762001607000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214426921001099"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":25,"alternative-id":["S2214426921001099"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgmr.2021.100814","relation":{},"ISSN":["2214-4269"],"issn-type":[{"value":"2214-4269","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Triheptanoin \u2013 Novel therapeutic approach for the ultra-rare disease mitochondrial malate dehydrogenase deficiency","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgmr.2021.100814","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100814"}}